[BAX] Baxter International Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.

 

Price: 44.21 Change: 0.05 (0.11%)
Ext. hours: Change: 0 (0%)

chart BAX

Refresh chart

Strongest Trends Summary For BAX

BAX is in the medium-term up 16% in 4 months. In the long-term up 104% in 5 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. Its BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and certain vaccines. The company?s Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; products and services related to pharmacy compounding, drug formulation, and packaging technologies; and technologies and therapies for peritoneal dialysis, in-center and home hemodialysis, and continuous renal replacement

Fundamental Ratios
Shares Outstanding EPS1.04 EPS Growth - 4 Quarters-41.96% EPS Growth - Q/Q-77.94%
EPS Growth - Y/Y41.76% Sales Growth - 4 Quarters -13.81% Sales Growth - Q/Q-15.83% P/E55.7
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA9.54% ROE32.67% ROI12.64%
Current Ratio1.6 Quick Ratio1.03 Long Term Debt/Equity2.1 Debt Ratio0.84
Gross Margin48.63% Operating Margin15.2% Net Profit Margin14.29% Dividend Payout Ratio-46.86%
Dividend Yield
Fundamental Data
Cash From Financing Activities384 M Cash From Investing Activities-770 M Cash From Operating Activities96 M Gross Profit1.92 B
Net Profit332 M Operating Profit435 M Total Assets24.86 B Total Current Assets9.73 B
Total Current Liabilities6.07 B Total Debt10.01 B Total Liabilities17.6 B Total Revenue3.89 B
Technical Data
High 52 week81.77 Low 52 week61.23 Last close74.33 Last change-0.08%
RSI14.09 Average true range1.4 Beta0.58 Volume1.84 M
Simple moving average 20 days-6.16% Simple moving average 50 days-2.81% Simple moving average 200 days3.66%
Performance Data
Performance Week-6.89% Performance Month-3.69% Performance Quart7.81% Performance Half3.87%
Performance Year11.16% Performance Year-to-date13.22% Volatility daily1.38% Volatility weekly3.08%
Volatility monthly6.32% Volatility yearly21.9% Relative Volume171.45% Average Volume2.88 M
New High New Low

News

2019-04-18 10:33:02 | Analysts Estimate Baxter International BAX to Report a Decline in Earnings: What to Look Out for

2019-04-17 14:31:37 | Why Qualcomm Is among Steve Cohen’s Top Bets

2019-04-16 16:15:00 | Baxter to Present at the Bank of America Merrill Lynch Health Care Conference 2019

2019-04-16 07:33:43 | How Baxter International Inc. NYSE:BAX Could Add Value To Your Portfolio

2019-04-15 08:15:44 | The Future Keeps Looking Better and Better for BAX Stock

2019-04-09 08:30:00 | Baxter Unveils the Latest Evolution of Floseal at AORN Meeting

2019-04-04 16:30:00 | Baxter to Host Webcast of Annual Meeting of Stockholders

2019-04-03 00:42:37 | Here is What Third Point Thinks About Baxter International Inc. BAX

2019-04-02 11:48:48 | See what the IHS Markit Score report has to say about Baxter International Inc.

2019-04-01 10:12:56 | Is Baxter International Inc.’s NYSE:BAX 14% ROCE Any Good?

2019-03-28 10:53:37 | Here is What Hedge Funds Think About Baxter International Inc. BAX Right Now

2019-03-28 09:54:01 | Baxter Showcases PN Product Portfolio at ASPEN Conference

2019-03-27 08:49:12 | Moving Average Crossover Alert: Baxter International

2019-03-26 16:35:00 | Baxter Highlights Advancements in Clinical Nutrition at ASPEN Conference

2019-03-26 06:00:00 | 3 Large-Cap Stocks Hitting 52-Week Highs: Are They Buys?

2019-03-25 08:37:12 | Fresenius Medical's New Hemodialysis Software Gets FDA Nod

2019-03-22 09:35:01 | Baxter BAX Soars to 52-Week High, Time to Cash Out?

2019-03-21 18:13:30 | MS Global Franchise Fund's Top 5 Buys of the 4th Quarter

2019-03-21 07:51:11 | Moving Average Crossover Alert: Baxter International

2019-03-19 18:38:01 | Morgan Stanley Institutional Global Franchise Fund Buys Baxter International Inc, Heineken NV

2019-03-19 14:31:06 | Top Analyst Reports for Home Depot, Oracle & Union Pacific

2019-03-19 12:08:04 | Baxter BAX Upgraded to Buy: Here's What You Should Know

2019-03-19 10:41:02 | Baxter's BAX New Tie Up to Boost Acute Therapies Business

2019-03-19 01:00:00 | Baxter and bioMérieux Announce Collaboration to Improve Identification and Treatment of Acute Kidney Injury

2019-03-17 09:50:40 | Could Baxter International Inc.’s NYSE:BAX Investor Composition Influence The Stock Price?

2019-03-12 10:24:41 | See what the IHS Markit Score report has to say about Baxter International Inc.

2019-03-07 08:33:01 | Baxter BAX Gets FDA Approval for Eptifibatide to Treat ACS

2019-03-06 08:00:28 | See what the IHS Markit Score report has to say about Baxter International Inc.

2019-03-06 08:00:00 | Baxter Announces U.S. FDA Approval and Launch of Ready-to-Use Cardiovascular Medicine Eptifibatide

2019-03-06 07:15:00 | Analysis: Positioning to Benefit within XPO Logistics, L3 Technologies, Domino's Pizza, Baxter International, Conduent, and Xylem — Research Highlights Growth, Revenue, and Consolidated Results

2019-03-05 09:15:00 | Baxter Honored as a 2019 “Top Company for Executive Women” by the National Association for Female Executives

2019-03-02 08:49:07 | If You Had Bought Baxter International Shares Three Years Ago You’d Have Made 89%

2019-02-28 17:50:02 | Dan Loeb’s Third Point Looks to Baxter and Campbell Soup in 2019

2019-02-22 16:11:39 | Daniel Loeb Comments on Baxter

2019-02-22 13:01:07 | U.S. closes IV solution shortage antitrust probe, Baxter says

2019-02-21 18:48:19 | Baxter International Inc BAX Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-02-19 08:45:00 | Baxter Declares Quarterly Dividend

2019-02-16 08:40:36 | Does Baxter International Inc. NYSE:BAX Have A Good P/E Ratio?

2019-02-14 09:07:02 | Baxter's Acute Therapies Profile Strong, Competition Rife

2019-02-13 16:15:00 | Baxter to Present at the Barclays Global Healthcare Conference

2019-02-12 08:54:10 | Dan Loeb Increased Third Point’s Position in These Stocks in Q4

2019-02-11 08:00:00 | Baxter and NantHealth® Advance Digital Health Technology for Medical Devices in the Hospital ICU

2019-02-06 16:15:00 | Baxter to Present at the Raymond James 40th Annual Institutional Investors Conference

2019-02-05 13:21:15 | Affiliate of Charlotte-based Premier partners with Baxter to make generic drugs more available

2019-02-05 10:30:02 | What Are Abbott Laboratories’ Key Growth Drivers in 2019?

2019-02-04 18:02:02 | [$$] Blood-Pressure Medicine Will Be First Product for New Generic Drug Venture

2019-02-04 07:25:00 | Report: Developing Opportunities within Ensco plc, Third Point Reinsurance, Baxter International, Ultrapar Participacoes S.A, Endeavour Silver, and Ingles Markets — Future Expectations, Projections Moving into 2019

2019-01-31 17:53:14 | Baxter BAX Q4 2018 Earnings Conference Call Transcript

2019-01-31 17:14:43 | Edited Transcript of BAX earnings conference call or presentation 31-Jan-19 1:30pm GMT

2019-01-31 11:42:04 | Baxter's BAX Earnings, Revenues Beat Estimates in Q4